EN | RU
EN | RU

Help Support

Back

Comparison of Teriparatide, Denosumab, and Bisphosphonates for osteoporosis prevention

Teriparatide, Denosumab, and Bisphosphonates Teriparatide, Denosumab, and Bisphosphonates
Teriparatide, Denosumab, and Bisphosphonates Teriparatide, Denosumab, and Bisphosphonates

A systematic review and meta-analysis was done to examine the safety and effectiveness of Denosumab and Teriparatide in relation to oral Bisphosphonates for averting glucocorticoid-induced osteoporosis.

See All

Key take away

For preventing glucocorticoid-induced osteoporosis, Teriparatide and Denosumab show similar or even superior benefits to Bisphosphonates.

Background

A systematic review and meta-analysis was done to examine the safety and effectiveness of Denosumab and Teriparatide in relation to oral Bisphosphonates for averting glucocorticoid-induced osteoporosis.

Method

A thorough search was performed across Cochrane Library, Embase, Web of Science, and PubMed databases to include relevant studies that entailed randomized controlled trials that contrasted Teriparatide or Denosumab with Bisphosphonates. Risk assessments were then pooled utilizing fixed and random effects models.

Result

In total, the meta-analysis encompassed 10 studies incorporating 2923 subjects treated with glucocorticoids. Overall, 4 sensitivity analyses and 2 drug base evaluations were involved. Teriparatide and Denosumab outperformed Bisphosphonates in enhancing lumbar vertebrae bone mineral density (BMD), as depicted in Table 1:

Additionally, Teriparatide exhibited superiority over Bisphosphonates in preventing vertebral fractures and elevating hip BMD (mean difference [MD] 2.39%). No notable statistical distinction was observed concerning nonvertebral fracture prevention drugs, adverse events, and severe adverse events. 

Conclusion

With their comparable or even superior attributes to Bisphosphonates, Teriparatide and Denosumab were promising as primary treatments for osteoporosis. These treatments hold promise as primary options for managing glucocorticoid-induced osteoporosis, particularly in cases where patients have previously encountered limited effectiveness with other anti-osteoporotic medications.

Source:

Journal of Orthopaedic Surgery and Research

Article:

Clinical efficacy of Denosumab, Teriparatide, and oral Bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

Authors:

Chuanjian Yuan et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: